Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215253 · ClinicalTrials.gov registry record · Phase 3
Ranolazine Implantable Cardioverter-Defibrillator Trial
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,012
- Enrollment target
NCT01215253 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 1,012 participants.
The verdict
NCT01215253, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,012 participants
- Enrollment target
Study Summary
The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2011-09 |
| Est. Completion | 2017-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215253
The ClinicalTrials.gov registry entry for NCT01215253 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01215253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215253 about?
NCT01215253 is a clinical study titled "Ranolazine Implantable Cardioverter-Defibrillator Trial". The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.
What is the current status of trial NCT01215253?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,012 participants. The study started on 2011-09. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT01215253?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01215253?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.